The Future of Retatrutide and Triple Agonists in Medical Weight Loss

Retatrutide represents the third generation of GLP-1 class obesity pharmacotherapy — and potentially the most powerful. With Phase 3 TRIUMPH data showing up to 28.8% average weight loss, retatrutide is approaching the efficacy of bariatric surgery in a once-weekly injectable format.

For medical weight loss clinics, the question is not whether retatrutide will reshape the market — it is how to position your practice to benefit from that reshaping.

Eli Lilly submitted the New Drug Application (NDA) for retatrutide in late 2025, based on the TRIUMPH Phase 3 data. The FDA's standard review timeline is 10–12 months from NDA submission.

Expected FDA approval: Mid-to-late 2026, pending FDA review.

Priority review: Eli Lilly has applied for priority review designation based on the unmet medical need in obesity. If granted, the review timeline shortens to 6 months.

Upon FDA approval, retatrutide will likely be branded and launched at a price point similar to tirzepatide ($900–$1,200/month retail). Insurance coverage will initially be limited, creating the same access gap that drove the compounded GLP-1 market.

This means the compounded retatrutide market — which already exists through 503A pharmacies — will likely expand significantly post-approval as patients seek affordable access.

Inadequate response to tirzepatide: Patients who have not achieved adequate weight loss on tirzepatide 15 mg are the primary candidates for retatrutide. The additional glucagon receptor agonism provides a third mechanism that can produce additional weight loss.

Patients with high weight loss goals: Patients who need to lose 25%+ of body weight to achieve their health goals may benefit from retatrutide's superior efficacy.

Metabolic syndrome with hepatic involvement: Retatrutide's glucagon receptor component has particularly strong effects on hepatic fat reduction — relevant for patients with NAFLD/MASH.

Patients seeking the most advanced option: Some patients are motivated by having access to the most advanced treatment available. Retatrutide satisfies this preference.

One concern with aggressive weight loss is muscle loss. Preliminary data from the TRIUMPH trials suggests retatrutide may preserve lean mass better than semaglutide, potentially due to the glucagon receptor's effects on protein metabolism.

Full body composition data from the TRIUMPH trials is expected with the complete publication. This data will be important for counseling patients about retatrutide vs. tirzepatide.

Retatrutide is currently available as a compounded preparation through 503A pharmacies for patient-specific prescriptions. This is permissible because retatrutide is not yet FDA-approved — the "essentially a copy" restriction does not apply to non-approved agents.

Current availability at MedClinic Partners: We supply compounded retatrutide as a special order through our 503A portal. Available as lyophilized powder, pre-constituted, and wet mix formulations.

Post-approval considerations: Once retatrutide receives FDA approval, the regulatory landscape for compounded retatrutide will change. The same "essentially a copy" analysis that applies to semaglutide and tirzepatide will apply to retatrutide. Practices that want to continue offering compounded retatrutide post-approval will need to ensure their formulations are clinically differentiated.

Practices that begin offering retatrutide now — through compounded preparations — will have established protocols, trained staff, and patient experience before FDA approval. This first-mover advantage is significant.

Develop retatrutide-specific:

• Patient selection criteria
• Dosing and titration protocols
• Monitoring protocols
• Informed consent documentation
• Patient education materials

IRB-approved research on retatrutide positions your practice as a research site. This is the most credible way to offer retatrutide and generates outcomes data that differentiates your practice.

Establish your retatrutide supply chain now. Post-approval demand will be significant, and practices with established supplier relationships will have supply security that new entrants will not.

Request portal access for retatrutide →

This content is for informational and educational purposes only. Retatrutide is not yet FDA-approved. It does not constitute medical advice. Prescribers should use clinical judgment.